Celemics셀레믹스
331920 · KOSDAQ · ₩331920 · 셀레믹스
- Market cap
- ₩103B
- Enterprise value
- ₩82B
- P/E
- —
- P/B
- 3.4×
- Dividend yield
- 0.0%
- ROE
- −33.5%
- Net margin
- −194.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−53.5% from the high
₩2,535Today: ₩8,340 – ₩9,220₩19,840
Returns
- 1W−6.0%
- 1M−18.8%
- 3M−13.8%
- 6M−45.2%
- YTD+239.6%
- 1Y+214.7%
- Volume today
- 62,650
- 1.1× the 20-day average
- Traded today
- ₩543M
- Listed shares
- 11,181,555
- EPS (12 months)
- −₩909
- Earnings yield −9.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+7.1% on Oct 27, 2026.
- • Foreign investors bought a net ₩17M that day
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumWeak-15.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Celemics stock overview
Celemics (셀레믹스, KRX: 331920) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean NGS-based genetic analysis technology platform firm that developed the MSSIC next-generation cloning technology. Its shares closed at ₩9,220 on Oct 27, 2026, up 7.08% on the day, giving it a market value of ₩103B.
Key facts
- Market cap
- ₩103B
- Sector
- Biotech & Pharma
- Latest price change
- +7.08%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean NGS-based genetic analysis technology platform firm that developed the MSSIC next-generation cloning technology.
Quick answers about Celemics
- What does Celemics do?
- The company is a Korean NGS-based genetic analysis technology platform firm that developed the MSSIC next-generation cloning technology. It produces and sells Target Capture kits and offers targeted sequencing services, immune repertoire analysis solutions, and the BTSeq sequencing solution. Its customers include hospitals, contract testing labs, pharmaceutical companies, seed companies, and research institutes, with applications in diagnostics, drug development, seed breeding, synthetic biology, and research.
- What is the market cap of Celemics?
- The market capitalisation of Celemics was ₩103B at the close on Oct 27, 2026.
- Who are the largest shareholders of Celemics?
- According to the latest official filings, the largest reported holders are Park Jong-gap (24.87%, as of Sep 10, 2026); Supigen New Technology Investment Partnership No. 1 (12.50%, as of Jun 8, 2026); Supi Show New Technology Investment Partnership No. 1 (11.12%, as of May 7, 2026).
- When is the next earnings report from Celemics?
- Korean companies rarely announce results dates in advance. Based on when Celemics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean NGS-based genetic analysis technology platform firm that developed the MSSIC next-generation cloning technology. It produces and sells Target Capture kits and offers targeted sequencing services, immune repertoire analysis solutions, and the BTSeq sequencing solution. Its customers include hospitals, contract testing labs, pharmaceutical companies, seed companies, and research institutes, with applications in diagnostics, drug development, seed breeding, synthetic biology, and research.
Written by AI from the company's latest annual report.
- Korean name
- 셀레믹스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박종갑, 김효기
- Founded
- Nov 2010
- Listed
- Aug 2020
- Listed shares
- 11,181,555
- Fiscal year ends
- Month 12
- Website
- www.celemics.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Notice on Grant of Stock Purchase OptionsOct 6, 2026
- Amended: Rights offering (paid-in capital increase) decisionSep 14, 2026
- 5%+ holding reportSep 10, 2026
- Insider shareholding reportSep 10, 2026
- Insider shareholding reportSep 3, 2026
Titles in Korean until English translations are added.
Also known as: Celemics / 셀레믹스 / 331920 / KRX:331920
Source: KRX statistical information